Background Anthracycline-induced cardiotoxicity in children with malignant diseases often may be associated with significant changes in values of some cardiac biomarkers.
Objective To establish the value of research of cardiac biomarkers for early diagnosis of anthracycline induced cardiotoxicity.
Methods Patients, 46 children (aged 2 months - 18 years), treated with anthracyclines for malignant hemopathies. Control group: 20 healthy children without history of cardiac diseases. Patients and controls were investgated by: clinical exam, Doppler echocardiography (Echo), determination of plasma values of of cardiac biomarkers BNP(B natriuretic peptide) and cTnI (troponin).
Results Determination of cardiac biomarkers: *Increased plasma levels of BNP in 45.7% of patients, from a mean baseline of 89 ng/ml (0–117 ng/ml) to alue 240 ng/ml (0–810 ng/ml),* increasing cTnI values. plasma at 4.34% of cases, the initial values < 0.04 pg/ml to values > 0.04 pg/ml in 2 cases. Echo modifications: anthracycline induced cardiomyopathy or just only diastolic dysfunction of LV in majority of cases, often correlated with cumulative dose of anthracyclines. Biomarkers changes were correlated in most cases with the presence of clinical manifestations and echo modifications induced by anthracycline cardiotoxicity.
Conclusions Clinical or infraclinical manifestations of cardiotoxicity in children treated with anthracyclines is associated with increased levels of cardiac biomarkers: BNP and cTnI which is an useful marker for the.cardiotoxicity. Changes in this parameters appeared early than echo modifications in anthracicline induced cardiotoxicity and is necessary to systematic monitoring these parameters during and after cytostatic therapy.